Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
Sudhan DR, Guerrero-Zotano A, Won H, González Ericsson P, Servetto A, Huerta-Rosario M, Ye D, Lee KM, Formisano L, Guo Y, Liu Q, Kinch LN, Red Brewer M, Dugger T, Koch J, Wick MJ, Cutler RE Jr, Lalani AS, Bryce R, Auerbach A, Hanker AB, Arteaga CL. Sudhan DR, et al. Among authors: gonzalez ericsson p. Cancer Cell. 2020 Feb 10;37(2):183-199.e5. doi: 10.1016/j.ccell.2019.12.013. Epub 2020 Jan 23. Cancer Cell. 2020. PMID: 31978326 Free PMC article.
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL. Schwarz LJ, et al. J Natl Cancer Inst. 2017 Nov 1;109(11):djx065. doi: 10.1093/jnci/djx065. J Natl Cancer Inst. 2017. PMID: 29059433 Free PMC article.
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, González Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Sudhan DR, et al. Clin Cancer Res. 2019 Jan 15;25(2):771-783. doi: 10.1158/1078-0432.CCR-18-1131. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274983 Free PMC article.
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.
Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE Jr, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL. Croessmann S, et al. Clin Cancer Res. 2019 Jan 1;25(1):277-289. doi: 10.1158/1078-0432.CCR-18-1544. Epub 2018 Oct 12. Clin Cancer Res. 2019. PMID: 30314968 Free PMC article.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Nixon MJ, Formisano L, Mayer IA, Estrada MV, González-Ericsson PI, Isakoff SJ, Forero-Torres A, Won H, Sanders ME, Solit DB, Berger MF, Cantley LC, Winer EP, Arteaga CL, Balko JM. Nixon MJ, et al. Among authors: gonzalez ericsson pi. NPJ Breast Cancer. 2019 Sep 23;5:31. doi: 10.1038/s41523-019-0126-6. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 31552290 Free PMC article.
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA; Translational Breast Cancer Research Consortium. Lehmann BD, et al. Clin Cancer Res. 2020 May 1;26(9):2111-2123. doi: 10.1158/1078-0432.CCR-19-2170. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822498 Free PMC article. Clinical Trial.
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.
Lee KM, Guerrero-Zotano AL, Servetto A, Sudhan DR, Lin CC, Formisano L, Jansen VM, González-Ericsson P, Sanders ME, Stricker TP, Raj G, Dean KM, Fiolka R, Cantley LC, Hanker AB, Arteaga CL. Lee KM, et al. Among authors: gonzalez ericsson p. Nat Commun. 2020 Oct 30;11(1):5488. doi: 10.1038/s41467-020-19291-x. Nat Commun. 2020. PMID: 33127913 Free PMC article.
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer.
Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, Arteaga CL. Servetto A, et al. Clin Cancer Res. 2021 Aug 1;27(15):4379-4396. doi: 10.1158/1078-0432.CCR-20-3905. Epub 2021 May 19. Clin Cancer Res. 2021. PMID: 34011560 Free PMC article.
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness.
Parida PK, Marquez-Palencia M, Nair V, Kaushik AK, Kim K, Sudderth J, Quesada-Diaz E, Cajigas A, Vemireddy V, Gonzalez-Ericsson PI, Sanders ME, Mobley BC, Huffman K, Sahoo S, Alluri P, Lewis C, Peng Y, Bachoo RM, Arteaga CL, Hanker AB, DeBerardinis RJ, Malladi S. Parida PK, et al. Among authors: gonzalez ericsson pi. Cell Metab. 2022 Jan 4;34(1):90-105.e7. doi: 10.1016/j.cmet.2021.12.001. Cell Metab. 2022. PMID: 34986341 Free PMC article.
50 results